AIDSWEEKLY Plus; Monday, July 19, 2004
Staff Medical Writers

According to investigators in the United States, "To examine effectiveness of subsequent antiretroviral therapy (ART), studies published during the period of 1 January 1997 through 31 May 2003 involving patients who had failed a protease inhibitor (PI)-containing regimen and were switched to another regimen were reviewed."

"Twelve studies describing 1197 patients were analyzed. A total of 38% of patients had human immunodeficiency virus (HIV) RNA levels of <500 copies/mL at 24 weeks," E. Losina and coworkers reported.

Losina continued, "After adjustment for baseline HIV RNA level, the rate of virologic suppression ranged from 16% for patients switching drugs within previously failed classes to 54% for nonnucleoside reverse-transcriptase inhibitor (NNRTI)-naive patients switched to boosted PI- and NNRTI-containing regimens.

"ART regimens in patients who failed a PI- containing regimen provided virologic suppression only in a few patients. The best response was seen in NNRTI-naive patients receiving NNRTI- and boosted PI-containing regimens."

The authors concluded, "New approaches are needed to achieve better suppression in pretreated HIV-infected patients."

Losina and colleagues published their study in Clinical Infectious Diseases (Effectiveness of antiretroviral therapy after protease inhibitor failure: An analytic overview. Clin Infect Dis. 2004 Jun 1;38(11):1613-22.

For more information, contact E. Losina, Boston University, School Publ Hlth, Department Biostatistics, 715 Albany St., Talbot 4-E, Boston, MA 02118 USA.

Publisher contact information for the journal Clinical Infectious Diseases is: University Chicago Press, 1427 E 60TH St., Chicago, IL 60637-2954 USA.

The information in this article comes under the major subject areas of HIV/AIDS, Antiretroviral Therapy, Genomics & Genetics and Drug Resistance.

This article was prepared by AIDS Weekly editors from staff and other reports.

Reference

Losina E, Islam R, Pollock AC, et al. "Effectiveness of antiretroviral therapy after protease inhibitor failure: an analytic overview", Clin Infect Dis. 2004 Jun 1;38(11):1613-22.

PubMED Related articles Search

040719
AW040709

Copyright © 2004 - Charles Henderson, Publisher. All rights Reserved. Permission to reproduce granted to AEGIS by Charles W. Henderson. Authorization to reproduce for personal use granted granted by C. W. Henderson, Publisher, provided that the fee of US$4.50 per copy, per page is paid directly to the Copyright Clearance Center, 27 Congress Street, Salem, Massachusetts 01970, USA. Published by Charles Henderson, Publisher. Editorial & Publishing Office: P.O. Box 5528, Atlanta, GA 30307-0528 / Telephone: (800) 633-4931; Subscription Office: P.O. Box 830409, Birmingham, AL 35283-0409 / FAX: (205) 995-1588 http://www.newsrx.net

AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Elton John AIDS Foundation, John M. Lloyd Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2004. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright © 1980,2004. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.